148580-09-0Relevant articles and documents
Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy
Florent, Jean-Claude,Dong, Xia,Gaudel, Gilbert,Mitaku, Sofia,Monneret, Claude,Gesson, Jean-Pierre,Jacquesy, Jean-Claude,Mondon, Martine,Renoux, Brigitte,Andrianomenjanahary, Solo,Michel, Sylvie,Koch, Michel,Tillequin, Fran?ois,Gerken, Manfred,Czech, Joerg,Straub, Rainer,Bosslet, Klaus
, p. 3572 - 3581 (2007/10/03)
A series of new prodrugs of daunorubicin and doxorubicin which are candidates for antibody-directed enzyme prodrug therapy (ADEPT) is reported. These compounds (25a,b,c and 32a,b,c) have been designed to generate cytotoxic drugs after activation with β-gl
Fluorescent molecular probes I. The synthesis and biological properties of an ELF β-glucuronidase substrate that yields fluorescent precipitates at the enzymatic activity sites
Diwu, Zhenjun,Lu, Yixin,Upson, Rosalyn H.,Zhou, Mingjie,Klaubert, Dieter H.,Haugland, Richard P.
, p. 7159 - 7164 (2007/10/03)
A novel quinazolinone-based fluorogenic β-glucuronidase substrate has been synthesized and evaluated. In this protocol, a partially protected salicyl glucuronide is oxidatively condensed with anthranilamide to afford the required quinazolinonyl glucuronic acid methyl ester that is readily deprotected to yield the desired glucuronide, known as ELF-97 glucuronide. The glucuronide is a sensitive fluorogenic β-glucuronidase substrate that yields a bright yellow-green fluorescent precipitate upon enzymatic reaction.